HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 275 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $15,262,783 | +270.8% | 291,497 | +188.1% | 0.00% | +200.0% |
Q1 2024 | $4,115,717 | -30.2% | 101,173 | -36.6% | 0.00% | -50.0% |
Q4 2023 | $5,895,231 | -18.5% | 159,503 | -15.7% | 0.00% | 0.0% |
Q3 2023 | $7,229,808 | +15.7% | 189,262 | +9.2% | 0.00% | 0.0% |
Q2 2023 | $6,249,200 | +1.1% | 173,252 | +7.1% | 0.00% | -33.3% |
Q1 2023 | $6,180,250 | +55.8% | 161,829 | +132.2% | 0.00% | +50.0% |
Q4 2022 | $3,966,385 | +88.4% | 69,708 | +31.0% | 0.00% | +100.0% |
Q3 2022 | $2,105,000 | -74.2% | 53,231 | -71.3% | 0.00% | -66.7% |
Q2 2022 | $8,174,000 | +141.6% | 185,777 | +119.0% | 0.00% | – |
Q1 2022 | $3,383,000 | -32.3% | 84,845 | -31.8% | 0.00% | -100.0% |
Q4 2021 | $5,000,000 | +100.6% | 124,330 | +103.0% | 0.00% | 0.0% |
Q3 2021 | $2,492,000 | -20.6% | 61,252 | -11.4% | 0.00% | 0.0% |
Q2 2021 | $3,139,000 | -24.9% | 69,126 | -31.1% | 0.00% | -50.0% |
Q1 2021 | $4,182,000 | -39.2% | 100,277 | -37.7% | 0.00% | -33.3% |
Q4 2020 | $6,877,000 | +139.4% | 161,006 | +47.3% | 0.00% | +50.0% |
Q3 2020 | $2,872,000 | -55.2% | 109,311 | -54.3% | 0.00% | -60.0% |
Q2 2020 | $6,414,000 | +3367.0% | 239,211 | +2222.4% | 0.01% | – |
Q1 2020 | $185,000 | -67.8% | 10,300 | -68.2% | 0.00% | -100.0% |
Q4 2019 | $574,000 | +85.2% | 32,357 | +62.1% | 0.00% | 0.0% |
Q3 2019 | $310,000 | -31.3% | 19,967 | -28.7% | 0.00% | – |
Q1 2019 | $451,000 | -26.8% | 27,986 | -17.5% | 0.00% | -100.0% |
Q3 2018 | $616,000 | +127.3% | 33,920 | +145.3% | 0.00% | 0.0% |
Q1 2018 | $271,000 | -72.1% | 13,829 | -71.1% | 0.00% | -66.7% |
Q4 2017 | $970,000 | +17.0% | 47,876 | +0.3% | 0.00% | +50.0% |
Q3 2017 | $829,000 | +148.9% | 47,747 | +83.6% | 0.00% | +100.0% |
Q2 2017 | $333,000 | +21.5% | 26,011 | -18.0% | 0.00% | -50.0% |
Q2 2016 | $274,000 | +35.6% | 31,702 | +48.8% | 0.00% | +100.0% |
Q1 2016 | $202,000 | +6.9% | 21,305 | +95.5% | 0.00% | 0.0% |
Q4 2015 | $189,000 | -33.7% | 10,900 | -48.6% | 0.00% | -50.0% |
Q3 2015 | $285,000 | -83.1% | 21,207 | -71.6% | 0.00% | -81.8% |
Q2 2015 | $1,683,000 | – | 74,544 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,816,162 | $195,784,000 | 9.33% |
BB BIOTECH AG | 5,846,564 | $57,764,000 | 2.74% |
QVT Financial LP | 4,556,090 | $45,014,000 | 2.44% |
Parametrica Management Ltd | 29,578 | $292,000 | 2.21% |
SECTORAL ASSET MANAGEMENT INC | 4,389,682 | $43,370,000 | 1.84% |
Belmont Global Advisors, Inc. | 257,000 | $2,539,000 | 1.83% |
HARVEY CAPITAL MANAGEMENT INC | 394,550 | $3,898,000 | 1.40% |
Lombard Odier Asset Management (USA) Corp | 1,350,000 | $13,338,000 | 0.70% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 6,199,685 | $61,253,000 | 0.63% |
Callan Capital, LLC | 199,230 | $1,968,000 | 0.53% |